Skip to search formSkip to main contentSkip to account menu

Cisplatin-Mitomycin-Vinblastine Regimen

Known as: MVP Regimen 
A regimen consisting of cisplatin, mitomycin and vinblastine used to treat advanced-stage non-small cell lung cancer.
National Institutes of Health

Related topics

Related topics

6 relations
CisplatinMVP regimenMitomycinNon-Small Cell Lung Carcinoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
[Chemotherapy of advanced non small cell lung cancer: effect on survival and symptoms affecting quality of life].
INTRODUCTION The study presents treatment results of 168 patients with non small cell lung cancer in stage IIIB and IV treated… 
2004
2004
[Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer].
OBJECTIVE To investigate the activity and clinical efficacy of toremifene plus mitomycin, vindesin and cisplatin regimen (MVP) in… 
2003
2003
Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
2002
2002
Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study.
2001
2001
Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC).
The majority of patients diagnosed with non-small cell lung carcinoma (NSCLC) present with advanced disease and, as such, are… 
2000
2000
A randomized phase III trial of the Southern Italy Oncology Group (G.O.I.M.). of mitomycin C plus vindesine and cisplatin (MVP regimen) versus vinorelbine plus cisplatin (PV regimen) in stage III–IV…
2000
2000
The relationship between the pathological changes and response rate (RR) in non-small cell lung cancer treated by neoadjuvant chemotherapy with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP…
Objective: To explore the change of pathology and the clinical response rate treated by neoadjuvant chemotherapy with MVP regimen… 
1998
1998
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the…
1992
1992
Renal Salt Wasting in Patients Treated with High-Dose Cisplatin, Etoposide, and Mitomycin in Patients with Advanced Non-Small Cell Lung Cancer
Cisplatin has many toxic effects; emesis, impairment of renal function, myelosuppression, peripheral neuropathy, ototoxicity and… 
1992
1992
Mitomycin C, Vindesine, and Cisplatin in Advanced Non‐Small-Cell Lung Cancer A Phase II Study
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)